* Portage Biotech Inc PRTG.OQ PRTG.O is expected to show
no
change in quarterly revenue when it reports results on July 31
(estimated).
*
* Refinitiv's mean analyst estimate for Portage Biotech Inc
is
for a loss of 27 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Portage
Biotech
Inc is $18.5, above its last closing price of $2.76.
This summary was machine generated July 28 at 15:01 GMT. All
figures in US dollars unless otherwise stated